Partner Mark Neuberger was quoted in a SHRM article, “Decline in Union Membership Expected After High Court Ruling,” about the anticipated fallout from the Supreme Court’s holding in Janus v. AFSCME Council 31, which banned mandatory union fees for public-sector employees.
Neuberger said the decision continues a trend that is developing in the private sector, where more and more states have passed laws outlawing all forms of mandatory union dues. It will also weaken the effectiveness of all public-sector unions in the states that had allowed compulsory agency fees, he said.
“On a grander scale, for good or for worse, this decision will lead to a further decline in the percentage of the American workforce that is unionized,” he added.
Neuberger said the decision continues a trend that is developing in the private sector, where more and more states have passed laws outlawing all forms of mandatory union dues. It will also weaken the effectiveness of all public-sector unions in the states that had allowed compulsory agency fees, he said.
“On a grander scale, for good or for worse, this decision will lead to a further decline in the percentage of the American workforce that is unionized,” he added.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”